- Home
- LOCO vs MREO Comparison
LOCO vs MREO Comparison
Compare LOCO & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOCO
- MREO
- Stock Information
- Founded
- LOCO 1980
- MREO 2015
- Country
- LOCO United States
- MREO United Kingdom
- Employees
- LOCO N/A
- MREO N/A
- Industry
- LOCO Restaurants
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- LOCO Consumer Discretionary
- MREO Health Care
- Exchange
- LOCO Nasdaq
- MREO Nasdaq
- Market Cap
- LOCO 323.7M
- MREO 311.8M
- IPO Year
- LOCO 2014
- MREO N/A
- Fundamental
- Price
- LOCO $10.53
- MREO $1.78
- Analyst Decision
- LOCO Buy
- MREO Strong Buy
- Analyst Count
- LOCO 2
- MREO 5
- Target Price
- LOCO $18.00
- MREO $7.40
- AVG Volume (30 Days)
- LOCO 338.7K
- MREO 1.5M
- Earning Date
- LOCO 10-30-2025
- MREO 11-12-2025
- Dividend Yield
- LOCO N/A
- MREO N/A
- EPS Growth
- LOCO 13.62
- MREO N/A
- EPS
- LOCO 0.89
- MREO N/A
- Revenue
- LOCO $480,815,000.00
- MREO $500,000.00
- Revenue This Year
- LOCO $6.13
- MREO N/A
- Revenue Next Year
- LOCO $1.56
- MREO $72.16
- P/E Ratio
- LOCO $11.81
- MREO N/A
- Revenue Growth
- LOCO 2.09
- MREO N/A
- 52 Week Low
- LOCO $8.29
- MREO $1.47
- 52 Week High
- LOCO $13.24
- MREO $4.40
- Technical
- Relative Strength Index (RSI)
- LOCO 64.09
- MREO 39.09
- Support Level
- LOCO $8.99
- MREO $1.98
- Resistance Level
- LOCO $10.83
- MREO $2.15
- Average True Range (ATR)
- LOCO 0.38
- MREO 0.12
- MACD
- LOCO 0.14
- MREO -0.04
- Stochastic Oscillator
- LOCO 83.74
- MREO 0.00
About LOCO El Pollo Loco Holdings Inc.
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).